– SEC Filing
Natera Announces Publication Of Largest Prospective dd-cfDNA Study In Kidney Transplantation
ProActive study shows Natera's Prospera Kidney™ test detects rejection five months before biopsyNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from